المؤلفون: Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., DeAngelo, D. J., Breccia, M., Goh, Y. -T., Talpaz, M., Hochhaus, A., le Coutre, P., Ottmann, O., Heinrich, M. C., Steegmann, J. L., Deininger, M. W. N., Janssen, J. J. W. M., Mahon, F. -X., Minami, Y., Yeung, D., Ross, D. M., Tallman, M. S., Park, J. H., Druker, B. J., Hynds, D., Duan, Y., Meille, C., Hourcade-Potelleret, F., Vanasse, K. G., Lang, F., Kim, D. -W.

المساهمون: Hughes, T. P., Mauro, M. J., Cortes, J. E., Minami, H., Rea, D., Deangelo, D. J., Breccia, M., Goh, Y. -T., Talpaz, M., Hochhaus, A., le Coutre, P., Ottmann, O., Heinrich, M. C., Steegmann, J. L., Deininger, M. W. N., Janssen, J. J. W. M., Mahon, F. -X., Minami, Y., Yeung, D., Ross, D. M., Tallman, M. S., Park, J. H., Druker, B. J., Hynds, D., Duan, Y., Meille, C., Hourcade-Potelleret, F., Vanasse, K. G., Lang, F., Kim, D. -W.

مصطلحات موضوعية: DIAGNOSED CHRONIC-PHASE, DOMAIN MUTATIONS, CLINICAL RESISTANCE, FOLLOW-UP, IMATINIB, CML, RECOMMENDATIONS, DASATINIB, SURVIVAL, IMPACT

العلاقة: volume:381; issue:24; firstpage:2315; lastpage:2326; numberofpages:12; journal:THE NEW ENGLAND JOURNAL OF MEDICINE; https://hdl.handle.net/11573/1690548Test

الإتاحة: https://doi.org/10.1056/NEJMoa1902328Test
https://hdl.handle.net/11573/1690548Test

المؤلفون: Giles, F J, le Coutre, P D, Pinilla-Ibarz, J, Larson, R A, Gattermann, N, Ottmann, O G, Hochhaus, A, Radich, J P, Saglio, G, Hughes, T P, Martinelli, G, Kim, D-W, Novick, S, Gillis, K, Fan, X, Cortes, J, Baccarani, M, Kantarjian, H M

مصطلحات موضوعية: nilotinib, imatinib resistance, imatinib intolerance, imatinib failure, tyrosine kinase inhibitors, early molecular response, chronic myelogenous leukemia, to-treat analysis, bcr-abl, selective inhibitor, line therapy, amn107, cml

العلاقة: Leukemia; Giles, F J; le Coutre, P D; Pinilla-Ibarz, J; Larson, R A; Gattermann, N; Ottmann, O G; Hochhaus, A; Radich, J P; Saglio, G; Hughes, T P; Martinelli, G; Kim, D-W; Novick, S; Gillis, K; Fan, X; Cortes, J; Baccarani, M; Kantarjian, H M (2012). Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase ii study. Leukemia 27 (1), 107-112; 0887-6924,1476-5551; http://hdl.handle.net/10379/11637Test

الإتاحة: https://doi.org/10.1038/leu.2012.181Test
http://hdl.handle.net/10379/11637Test

المؤلفون: Giles, F J, Kantarjian, H M, le Coutre, P D, Baccarani, M, Mahon, F-X, Blakesley, R E, Gallagher, N J, Gillis, K, Goldberg, S L, Larson, R A, Hochhaus, A, Ottmann, O G

مصطلحات موضوعية: nilotinib, chronic myeloid leukemia, blastic phase, bcr-abl, imatinib resistance, mutations, chronic myelogenous leukemia, tyrosine kinase inhibitors, formerly amn107, dasatinib, cml, therapy, crisis, transformation, failure, cells

العلاقة: Leukemia; Giles, F J; Kantarjian, H M; le Coutre, P D; Baccarani, M; Mahon, F-X; Blakesley, R E; Gallagher, N J; Gillis, K; Goldberg, S L; Larson, R A; Hochhaus, A; Ottmann, O G (2011). Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26 (5), 959-962; 0887-6924,1476-5551; http://hdl.handle.net/10379/11636Test

الإتاحة: https://doi.org/10.1038/leu.2011.355Test
http://hdl.handle.net/10379/11636Test

المؤلفون: MORI, SILVIA, Vagge, E, le Coutre, P, Abruzzese, E, Martino, B, Pungolino, E, Elena, C, Pierri, I, Assouline, S, D'Emilio, A, Gozzini, A, Giraldo, P, Stagno, F, Iurlo, A, Luciani, M, De Riso, G, Kim, D, PIROLA, ALESSANDRA, Petroccione, A, Lodolo D’Oria, A, Crivori, P, PIAZZA, ROCCO GIOVANNI, GAMBACORTI PASSERINI, CARLO

المساهمون: Mori, S, Vagge, E, le Coutre, P, Abruzzese, E, Martino, B, Pungolino, E, Elena, C, Pierri, I, Assouline, S, D'Emilio, A, Gozzini, A, Giraldo, P, Stagno, F, Iurlo, A, Luciani, M, De Riso, G, Kim, D, Pirola, A, Petroccione, A, Lodolo D’Oria, A, Crivori, P, Piazza, R, GAMBACORTI PASSERINI, C

مصطلحات موضوعية: dPCR, Q-RT-PCR, imatinib discontinuation, CML, relapse

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000349242705155; ispartofbook:56th ASH Annual Meeting and Exposition; Annual Meeting American Society of Hematology (ASH) December 6-9; volume:124; issue:21; journal:BLOOD; http://hdl.handle.net/10281/105757Test

الإتاحة: https://doi.org/10.1182/blood.V124.21.813.813Test
http://hdl.handle.net/10281/105757Test

المؤلفون: Hochhaus, A., Masszi, T., Giles, F. J., Radich, J. P., Ross, D. M., Gomez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., Garcia-Gutierrez, V., Gattermann, N., Wiktor-Jedrzejczak, W., le Coutre, P. D., Martino, B., Saussele, S., Menssen, H. D., Deng, W., Krunic, N., Bedoucha, V., Saglio, G.

المصدر: Hochhaus , A , Masszi , T , Giles , F J , Radich , J P , Ross , D M , Gomez Casares , M T , Hellmann , A , Stentoft , J , Conneally , E , Garcia-Gutierrez , V , Gattermann , N , Wiktor-Jedrzejczak , W , le Coutre , P D , Martino , B , Saussele , S , Menssen , H D , Deng , W , Krunic , N , Bedoucha , V & Saglio , G 2017 , ' Treatment-free remission following frontline nilotinib in patients with chronic ....

مصطلحات موضوعية: INHIBITOR WITHDRAWAL SYNDROME, TYROSINE KINASE INHIBITORS, DEEP MOLECULAR RESPONSE, EURO-SKI TRIAL, MUSCULOSKELETAL PAIN, IMATINIB, DISCONTINUATION, CML, CESSATION, DISEASE

العلاقة: https://pure.au.dk/portal/en/publications/b1960460-55dd-45d0-b0f8-26a449ecc7f4Test

الإتاحة: https://doi.org/10.1038/leu.2017.63Test
https://pure.au.dk/portal/en/publications/b1960460-55dd-45d0-b0f8-26a449ecc7f4Test

المؤلفون: GAMBACORTI PASSERINI, CARLO, ANTOLINI, LAURA, Mahon, FX, Guilhot, F, Deininger, M, Fava, C, Nagler, A, Della Casa, CM, Morra, E, Abruzzese, E, D'Emilio, A, Stagno, F, le Coutre, P, Monroy, RH, Santini, V, Martino, B, Pane, F, Piccin, A, Giraldo, P, Assouline, S, Durosinmi, MA, Leeksma, O, POGLIANI, ENRICO MARIA, PUTTINI, MIRIAM, Jang, E, Reiffers, J, VALSECCHI, MARIA GRAZIA, Kim, DW

المساهمون: GAMBACORTI PASSERINI, C, Antolini, L, Mahon, F, Guilhot, F, Deininger, M, Fava, C, Nagler, A, Della Casa, C, Morra, E, Abruzzese, E, D'Emilio, A, Stagno, F, le Coutre, P, Monroy, R, Santini, V, Martino, B, Pane, F, Piccin, A, Giraldo, P, Assouline, S, Durosinmi, M, Leeksma, O, Pogliani, E, Puttini, M, Jang, E, Reiffers, J, Valsecchi, M, Kim, D

مصطلحات موضوعية: CML, imatinib, CCyR, long term effect, MED/06 - ONCOLOGIA MEDICA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/21422402; info:eu-repo/semantics/altIdentifier/wos/WOS:000289307800008; volume:103; issue:7; firstpage:553; lastpage:561; journal:JOURNAL OF THE NATIONAL CANCER INSTITUTE; http://hdl.handle.net/10281/20238Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-79953880772

الإتاحة: https://doi.org/10.1093/jnci/djr060Test
http://hdl.handle.net/10281/20238Test

المؤلفون: KANTARJIAN HM, GILES F, GATTERMANN N, BHALLA K, PALANDRI F, OSSENKOPPELE GJ, NICOLINI FE, O'BRIEN SG, LITZOW M, BHATIA R, CERVANTES F, HAQUE A, SHOU Y, RESTA DJ, WEITZMAN A, HOCHHAUS A, LE COUTRE P., ALIMENA, Giuliana

المساهمون: Kantarjian, Hm, Giles, F, Gattermann, N, Bhalla, K, Alimena, Giuliana, Palandri, F, Ossenkoppele, Gj, Nicolini, Fe, O'Brien, Sg, Litzow, M, Bhatia, R, Cervantes, F, Haque, A, Shou, Y, Resta, Dj, Weitzman, A, Hochhaus, A, LE COUTRE, P.

مصطلحات موضوعية: CHRONIC MYELOID-LEUKEMIA, IN-VITRO ACTIVITY, CYTOGENETIC RESPONSES, BLAST CRISIS, THERAPY, DASATINIB, MESYLATE, BIOLOGY, DISEASE, CML

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/17715389; info:eu-repo/semantics/altIdentifier/wos/WOS:000250946300016; volume:110; firstpage:3540; lastpage:3546; numberofpages:7; journal:BLOOD; http://hdl.handle.net/11573/31970Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-36348968931; http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000250946300016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0c7ff228ccbaaa74236f48834a34396aTest; http://www.ncbi.nlm.nih.gov/pubmed/17715389Test; http://www.scopus.com/inward/record.url?eid=2-s2.0-36348968931&partnerID=65&md5=47b4bba4f71d2b756d6444d242370873Test

الإتاحة: https://doi.org/10.1182/blood-2007-03-080689Test
http://hdl.handle.net/11573/31970Test
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000250946300016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=0c7ff228ccbaaa74236f48834a34396aTest
http://www.ncbi.nlm.nih.gov/pubmed/17715389Test
http://www.scopus.com/inward/record.url?eid=2-s2.0-36348968931&partnerID=65&md5=47b4bba4f71d2b756d6444d242370873Test

المؤلفون: Gambacorti-Passerini C., Le Coutre P., Mologni L., Fanelli M., Bertazzoli C., Marchesi E., Di Nicola M., Biondi A., Corneo G. M., Belotti D., Pogliani E., Lydon N. B.

المساهمون: Gambacorti-Passerini, C, Le Coutre, P, Mologni, L, Fanelli, M, Bertazzoli, C, Marchesi, E, Di Nicola, M, Biondi, A, Corneo, G, Belotti, D, Pogliani, E, Lydon, N

مصطلحات موضوعية: ALL, Apoptosi, BCR/ABL, CML, Tyrosine kinase inhibitor, Benzamide, Cell Differentiation, Cell Division, Cell Line, Fusion Proteins, bcr-abl, Human, Imatinib Mesylate, Leukemia, Myeloid, Phosphorylation, Piperazine, Protein-Tyrosine Kinase, Pyrimidine, Tumor Cells, Cultured

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/9446752; info:eu-repo/semantics/altIdentifier/wos/WOS:A1997YB21300001; volume:23; issue:3; firstpage:380; lastpage:394; numberofpages:15; journal:BLOOD CELLS, MOLECULES, & DISEASES; http://hdl.handle.net/10281/350653Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-0031409736

الإتاحة: https://doi.org/10.1006/bcmd.1997.0155Test
http://hdl.handle.net/10281/350653Test